1. Home
  2. BLNK vs DCTH Comparison

BLNK vs DCTH Comparison

Compare BLNK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.71

Market Cap

89.3M

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.32

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
DCTH
Founded
2009
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.3M
350.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BLNK
DCTH
Price
$0.71
$10.32
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$2.13
$22.60
AVG Volume (30 Days)
7.5M
527.6K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$106,631,000.00
$79,603,000.00
Revenue This Year
N/A
$131.69
Revenue Next Year
$17.87
$39.22
P/E Ratio
N/A
$299.08
Revenue Growth
N/A
251.54
52 Week Low
$0.63
$8.12
52 Week High
$2.65
$18.23

Technical Indicators

Market Signals
Indicator
BLNK
DCTH
Relative Strength Index (RSI) 24.55 60.66
Support Level $0.77 $9.92
Resistance Level $0.85 $10.44
Average True Range (ATR) 0.08 0.41
MACD -0.01 0.04
Stochastic Oscillator 2.97 68.87

Price Performance

Historical Comparison
BLNK
DCTH

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: